CompletedNCT01812642
A Pharmacokinetics Study to Evaluate Safety and Tolerability of JNJ-37822681 in Participants With Stable Schizophrenia
This study evaluated the safety of JNJ-37822681 for people with schizophrenia.
Medication studyAges 20–55Multiple countries
Understand this study
What did researchers investigate?
This study evaluated the safety of JNJ-37822681 for people with schizophrenia.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 20 years to 55 years. Other eligibility criteria applied.
- Listed locations
- Antwerp and 5 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateJuly 2008
- Recruitment status
- Completed
- Enrollment listed in the registry
- 33
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug, OTHER
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Belgium, Germany, Russia, ...
- Age range
- From 20 Years to 55 Years
- Official registry ID
- NCT01812642
- Official title
Show the full official title
A Double-Blind, Multiple Dose Titration Study to Investigate the Safety, Tolerability and Pharmacokinetics of Once Daily and Twice Daily Doses of JNJ-37822681 in Male and Female Patients With Stable Schizophrenia
Recruitment & locations
CompletedAntwerp, Belgium · Berlin, Germany · Neuss, Germany
4 more locations
- Nizny Novgorod, Russia
- Bratislava, Slovakia
- Stockholm, Sweden
- Russia
Questions about this study
What did researchers investigate?
This study evaluated the safety of JNJ-37822681 for people with schizophrenia.
Who is behind this study?
The study sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including JNJ-37822681.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 20 years to 55 years. Other eligibility criteria applied.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meRelated studies
A 12-WEEK, MULTICENTER, OPEN-LABEL EXTENSION STUDY IN SUBJECTS WITH SCHIZOPHRENIA
A 12-Week, Open-Label Extension Study of Lurasidone (SM-13496) in Subjects with Schizophrenia